Observed Signal · Aug 26, 2026 · corporate_event · Source: SEC API · Impact: 3.8/5

6-K Financial Filing Analysis for KNOREX (2026-08-26)

Executive Signal Summary

On August 21, 2026, KNOREX Ltd. received a deficiency notice from NYSE Regulation regarding non-compliance with NYSE American continued listing standards under Sections 1003(a)(i) and 1003(a)(ii). The non-compliance stems from consecutive net losses over the last four fiscal years and a stockholders' deficit of $(6.5) million as of December 31, 2025, against minimum stockholders' equity requirements of $2.0 million to $4.0 million. The company plans to submit a compliance plan by September 20, 2026, seeking to regain compliance by February 21, 2028, during which its Class A ordinary shares will continue trading normally subject to NYSE acceptance and progress milestones.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Receipt of a stock exchange non-compliance notice signals material balance sheet distress and creates imminent delisting risk if KNOREX fails to raise equity capital or restructure its balance sheet.

MARKET SIGNALS

Track KNOREX Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • KNOREX received an NYSE American non-compliance notice on August 21, 2026, due to a reported stockholders' deficit of $(6.5) million as of December 31, 2025, and four consecutive years of net losses.
  • The company must submit a compliance plan by September 20, 2026, to demonstrate how it will meet the equity threshold by February 21, 2028.
  • Trading of Class A ordinary shares continues unaffected during the cure period, but failure to submit an acceptable plan or meet milestones will trigger delisting proceedings.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: SEC API•Published: Aug 26, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

financialsAug 19, 2026

20-F Financial Filing Analysis for KNOREX (2026-08-19)

KNOREX LTD. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, reporting total revenue of approximately $6.04 million, representing a 44% year-over-year decline compared to $10.81 million in FY2024. The contraction was primarily driven by a substantial spending reduction from its largest customer (whose revenue contribution fell from 73.3% in FY2024 to 40.6% in FY2025) after that customer's key client was impacted by increased U.S. import tariffs. Gross profit declined from $4.5 million in 2024 to $2.9 million in 2025, while active customer count fell to 26 from 37 amid customer portfolio realignments. The company incurred a working capital deficit of $7.7 million, raising substantial doubt about its ability to continue as a going concern, though it secured a post-period $3.0 million note financing and an up to $50.0 million share purchase facility in March 2026.

Read assessment
financialsOct 28, 2026

6-K Financial Filing Analysis for KNOREX (2026-10-28)

Knorex Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 28, 2026, furnishing its unaudited condensed consolidated financial statements and operating and financial review for the six months ended June 30, 2026, and 2025. The filing serves as the company's semi-annual financial disclosure required for foreign private issuers, incorporating interim financial results in Exhibit 99.1 and accompanying management commentary in Exhibit 99.2.

Read assessment
Regulation & AntitrustNov 13, 2026

KNOREX Faces Delisting as NYSE American Suspends Class A Ordinary Shares

On November 11, 2026, KNOREX Ltd. was notified by NYSE American LLC that the exchange immediately suspended trading in its Class A ordinary shares and commenced proceedings to delist the stock under Section 1003(f)(v) of the NYSE American Company Guide due to an abnormally low selling price. KNOREX intends to appeal the decision by requesting a hearing before the Listing Qualifications Panel prior to the November 18, 2026 deadline. During the appeal, shares will remain suspended from trading. To regain compliance and defend its listing, the company plans to pursue a reverse stock split, though no assurance can be given regarding a successful outcome.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for KNOREX & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context